438 related articles for article (PubMed ID: 32293641)
21. Familial pityriasis rubra pilaris is caused by mutations in CARD14.
Fuchs-Telem D; Sarig O; van Steensel MA; Isakov O; Israeli S; Nousbeck J; Richard K; Winnepenninckx V; Vernooij M; Shomron N; Uitto J; Fleckman P; Richard G; Sprecher E
Am J Hum Genet; 2012 Jul; 91(1):163-70. PubMed ID: 22703878
[TBL] [Abstract][Full Text] [Related]
22. Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review.
Chandy RJ; Chokshi A; Tan I; Feldman SR
J Cutan Med Surg; 2024; 28(3):269-275. PubMed ID: 38549359
[TBL] [Abstract][Full Text] [Related]
23. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab.
Signa S; Campione E; Rusmini M; Chiesa S; Grossi A; Omenetti A; Caorsi R; Viglizzo GM; Galluzzo M; Bianchi L; Talamonti M; Orlandi A; Martini A; Ceccherini I; Gattorno M
Pediatr Rheumatol Online J; 2019 Jul; 17(1):38. PubMed ID: 31286971
[TBL] [Abstract][Full Text] [Related]
24. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40.
Matsuda T; Yamazaki F; Ueda-Hayakawa I; Kambe N; Okamoto H
J Dermatol; 2019 Jan; 46(1):70-72. PubMed ID: 30506728
[TBL] [Abstract][Full Text] [Related]
25. Increased epidermal expression and absence of mutations in CARD14 in a series of patients with sporadic pityriasis rubra pilaris.
Eytan O; Qiaoli L; Nousbeck J; van Steensel MA; Burger B; Hohl D; Taïeb A; Prey S; Bachmann D; Avitan-Hersh E; Jin Chung H; Shemer A; Trau H; Bergman R; Fuchs-Telem D; Warshauer E; Israeli S; Itin PH; Sarig O; Uitto J; Sprecher E
Br J Dermatol; 2014 May; 170(5):1196-8. PubMed ID: 24359224
[No Abstract] [Full Text] [Related]
26. Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris.
Rahman SM; Ahmed F; Haque A
Arch Dermatol Res; 2024 Jun; 316(6):334. PubMed ID: 38844710
[TBL] [Abstract][Full Text] [Related]
27. Genetic analysis of CARD14 in non-familial pityriasis rubra pilaris: a case series.
Hong JB; Chen PL; Chen YT; Tsai TF
Acta Derm Venereol; 2014 Sep; 94(5):587-8. PubMed ID: 24577624
[No Abstract] [Full Text] [Related]
28. Treatment Options for Juvenile Pityriasis Rubra Pilaris.
Guenther J; Novack D; Kamath S; Worswick S
Paediatr Drugs; 2023 Mar; 25(2):151-164. PubMed ID: 36529810
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris.
Boyd AH; Polcari IC
Pediatr Dermatol; 2018 Jan; 35(1):e62-e63. PubMed ID: 29044698
[TBL] [Abstract][Full Text] [Related]
30. Exacerbation of pityriasis rubra pilaris under efalizumab therapy.
Klein A; Szeimies RM; Landthaler M; Karrer S
Dermatology; 2007; 215(1):72-5. PubMed ID: 17587845
[TBL] [Abstract][Full Text] [Related]
31. Updates on Pityriasis Rubra Pilaris: A Scoping Review.
Zhou T; Al Muqrin A; Abu-Hilal M
J Cutan Med Surg; 2024; 28(2):158-166. PubMed ID: 38174859
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of CARD14-negative juvenile Pityriasis rubra pilaris with Ustekinumab.
Reitmajer M; Forchhammer S; Silber T
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e512-e514. PubMed ID: 38084925
[No Abstract] [Full Text] [Related]
33. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
34. Erythrodermic pityriasis rubra pilaris: Dramatic response to infliximab therapy.
Karadag AS; Kavala M; Ozlu E; Ozkanlı S; Zindancı İ; Turkoglu Z
Indian J Dermatol Venereol Leprol; 2016; 82(1):112. PubMed ID: 26728835
[No Abstract] [Full Text] [Related]
35. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
[TBL] [Abstract][Full Text] [Related]
36. A Review on Pityriasis Rubra Pilaris.
Wang D; Chong VC; Chong WS; Oon HH
Am J Clin Dermatol; 2018 Jun; 19(3):377-390. PubMed ID: 29302927
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with ustekinumab in CARD14-associated papulosquamous eruption in a Brazilian child.
Kiszewski AE; De Almeida HL
Dermatol Ther; 2022 Dec; 35(12):e15939. PubMed ID: 36239488
[TBL] [Abstract][Full Text] [Related]
38. Immune-regulatory genes as possible modifiers of familial pityriasis rubra pilaris - lessons from a family with PRP and psoriasis.
Spoerri I; Herms S; Eytan O; Sarig O; Heinimann K; Sprecher E; Itin PH; Burger B
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):e389-e392. PubMed ID: 29704870
[No Abstract] [Full Text] [Related]
39. Altered replication stress response due to CARD14 mutations promotes recombination-induced revertant mosaicism.
Miyauchi T; Suzuki S; Takeda M; Peh JT; Aiba M; Natsuga K; Fujita Y; Takeichi T; Sakamoto T; Akiyama M; Shimizu H; Nomura T
Am J Hum Genet; 2021 Jun; 108(6):1026-1039. PubMed ID: 34004138
[TBL] [Abstract][Full Text] [Related]
40. A child with CARD14-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab.
Nogueira M; Reis J; Abreu M; Coelho A; Reis CF; Machado S
Pediatr Dermatol; 2023; 40(6):1104-1106. PubMed ID: 37219506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
